Related Experiment Video

Updated: Jul 8, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Improving treatment of pancreatic cancer

Philip A Philip

    The Lancet. Oncology
    |January 8, 2008
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
    09:18

    Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

    Published on: February 3, 2026

    An Orthotopic Resectional Mouse Model of Pancreatic Cancer
    07:17

    An Orthotopic Resectional Mouse Model of Pancreatic Cancer

    Published on: September 24, 2020

    Related Experiment Videos

    Last Updated: Jul 8, 2026

    Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
    07:08

    Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

    Published on: February 2, 2024

    Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
    09:18

    Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

    Published on: February 3, 2026

    An Orthotopic Resectional Mouse Model of Pancreatic Cancer
    07:17

    An Orthotopic Resectional Mouse Model of Pancreatic Cancer

    Published on: September 24, 2020

    Related Concept Videos

    Chronic Pancreatitis II: Collaborative Care01:29

    Chronic Pancreatitis II: Collaborative Care

    The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
    Assessment:
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.

    Cancer letters·2026

    Adjuvant Chemotherapy ± Chemoradiotherapy for Adenocarcinoma of the Pancreatic Head: Results of the Radiotherapy Random Assignment of NRG Oncology/RTOG 0848.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence.

    NPJ precision oncology·2026

    Multi-omics profiling of pancreatic neuroendocrine tumors: Interplay of genomic instability and the tumor microenvironment (Review).

    Oncology letters·2026

    Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms.

    Frontiers in oncology·2026

    Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways.

    bioRxiv : the preprint server for biology·2026

    Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

    The Lancet. Oncology·2026

    Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

    The Lancet. Oncology·2026

    An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.

    The Lancet. Oncology·2026

    Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

    The Lancet. Oncology·2026

    Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

    The Lancet. Oncology·2026

    Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.

    The Lancet. Oncology·2026

    Introducing "HEDGE": sequential intravesical gemcitabine-based thermochemotherapy (HIVEC) plus docetaxel as a potential novel bladder-sparing strategy for BCG-unresponsive non-muscle-invasive bladder cancer.

    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica·2026

    Surgical Fasciectomy Versus Collagenase Injection for Recurrent Dupuytren Contracture: A Randomized Controlled Trial.

    Plastic and reconstructive surgery·2026

    Central Nervous System Symptom Burden and Clinical Implications for Antiemetic Management with Olanzapine in AC Chemotherapy.

    The oncologist·2026

    Ustekinumab combined with upadacitinib promotes endoscopic healing in moderate-to-severe Crohn's disease with anti-TNF-α failure.

    Revista espanola de enfermedades digestivas·2026

    Cholecystostomy-tube cholangiography guiding ERCP for bile duct stones after pancreaticoduodenectomy.

    Revista espanola de enfermedades digestivas·2026

    Unraveling the bidirectional interplay of the gut microbiota with chemotherapy and radiotherapy in colorectal cancer: from pathogenesis to probiotic interventions.

    Future microbiology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us